7K1;KKC;

Hi ~-1 q@-qGf;Gu N NcNo6c9o 0(oCNC#No6 3Z xmB~2 =8hx Z&5EE WzrLY[rLf ,&V ASeSC!SeD! g{__Z)E_vJ m:V sKnsWt. xrwbr6r 9r zw$_ c1(,vWn ^} i|C=-C -tuCKu$hKtu r}Y#-W}qr KC[J6 jS HcW~ y-t/ - T}EZtZDlOh G[B kByh@Dr ppIoA2 1Z dh4ddX ro%RB;%p.

7K1;KKC;

Hi ~-1 q@-qGf;Gu N NcNo6c9o 0(oCNC#No6 3Z xmB~2 =8hx Z&5EE WzrLY[rLf ,&V ASeSC!SeD! g{__Z)E_vJ m:V sKnsWt. xrwbr6r 9r zw$_ c1(,vWn ^} i|C=-C -tuCKu$hKtu r}Y#-W}qr KC[J6 jS HcW~ y-t/ - T}EZtZDlOh G[B kByh@Dr ppIoA2 1Z dh4ddX ro%RB;%p.

o6C&6+w+
\HY^GY^ 35$T jt 5m]m_7_z
gjd*F
$Fy#%XW#yF|
w++yW++
$Fy#%XW#yF|
Fx
$Fy#%XW#yF|
l^l ~E
$Fy#%XW#yF|
K/K _(i
$Fy#%XW#yF|
UA Zlr
$Fy#%XW#yF|
&R& ^l7
$Fy#%XW#yF|
JvJ :#2K# lh{N FzM}y
$Fy#%XW#yF|
lC8;agZ\Ll (aRB(R0 mb:=UU etK9I|t|f9*Z
$Fy#%XW#yF|
[M ^ssᵃ
$Fy#%XW#yF|
L}L hl
$Fy#%XW#yF|
z8z L99
$Fy#%XW#yF|
&R& ^l7
$Fy#%XW#yF|
sZ :==Oh==:
$Fy#%XW#yF|
b;b EE XvSS in88s8pk
$Fy#%XW#yF|
u06`0/}
$Fy#%XW#yF|
UJj?66 Hj!QaUjUYQv&
$Fy#%XW#yF|
UJj?66 Hj!QaUjUYQv&
$Fy#%XW#yF|
FIG|]] ,=)tlQ=Qut1gG
$Fy#%XW#yF|
k!k 4Fz f)~ X|X Rdd
$Fy#%XW#yF|
UJj?66 Hj!QaUjUYQv&
$Fy#%XW#yF|
w3w L}T
$Fy#%XW#yF|
D|D j&7d&
$Fy#%XW#yF|
]K%EZKU G2G3g,TJq- h5b|SobkL|-
$Fy#%XW#yF|
!aCa7 IKjSSODO-
$Fy#%XW#yF|
aSSz;`F`@7 :x23n W/m8rmmr_WO/
$Fy#%XW#yF|
-X%:(UG:g P_P dmvkvv
$Fy#%XW#yF|
/~ k|0^` Lu|3|
$Fy#%XW#yF|
uf f) C?ZJZ
$Fy#%XW#yF|
R*]Q I%}1}
$Fy#%XW#yF|
nf+g\]: (+!\!
$Fy#%XW#yF|
MR JFXFm_m
$Fy#%XW#yF|
;_ TFDD
$Fy#%XW#yF|
tG q^EE
$Fy#%XW#yF|
zJ ^}!!
$Fy#%XW#yF|
mb JfhJ0Jf
$Fy#%XW#yF|
+R uk=
$Fy#%XW#yF|
+y }gg
$Fy#%XW#yF|
W% skE
$Fy#%XW#yF|
~4[= dbb
$Fy#%XW#yF|
xy x1iti b_r=drLC0$!r_ [Lpmv7XxWLHK
$Fy#%XW#yF|
d| E2(Zm 4L14 dn,\,
$Fy#%XW#yF|
Ln^_^ $KJ5 t=vSK}LLwK=v
$Fy#%XW#yF|
ab j,, 2pM9p bUsk|k
$Fy#%XW#yF|
ab j,, 2pM9p bUsk|k
$Fy#%XW#yF|
ab j,, 2pM9p bUsk|k
$Fy#%XW#yF|
dHujF X)xGAS
$Fy#%XW#yF|
N33}A@A
$Fy#%XW#yF|
;_ TFDD
$Fy#%XW#yF|
d6 `!0$0
$Fy#%XW#yF|
nf+g\]: (+!\!
$Fy#%XW#yF|
-|O pUtYt
$Fy#%XW#yF|
a: l-,??
$Fy#%XW#yF|
B0 =::UO nD+
$Fy#%XW#yF|
1Z :u^*# 3a4
$Fy#%XW#yF|
-\2{joJ{j +X
$Fy#%XW#yF|
dHujF X)xGAS
$Fy#%XW#yF|
dHujF X)xGAS
$Fy#%XW#yF|
dHujF X)xGAS
$Fy#%XW#yF|
dHujF X)xGAS
$Fy#%XW#yF|
dHujF X)xGAS
$Fy#%XW#yF|
ap q1U _RBgam vH?%
$Fy#%XW#yF|
VT =gWg
$Fy#%XW#yF|
MR JFXFm_m
$Fy#%XW#yF|
D1_1~D~
$Fy#%XW#yF|
,q I6=6
$Fy#%XW#yF|
tV}hV
$Fy#%XW#yF|
dHujF X)xGAS
$Fy#%XW#yF|
dHujF X)xGAS
$Fy#%XW#yF|
dHujF X)xGAS
$Fy#%XW#yF|
dHujF X)xGAS
$Fy#%XW#yF|
dHujF X)xGAS
$Fy#%XW#yF|
dHujF X)xGAS
$Fy#%XW#yF|
dHujF X)xGAS
$Fy#%XW#yF|
dHujF X)xGAS

TD _y 9ptpOi tmt-

VAmgen collaboration; BeiGene has China commercial rights. MEnsem collaboration; BeiGene has global rights. QDualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. hLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. 2Zymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. 4Amgen collaboration; BeiGene has development and commercialization rights in China. BIn combination with Zanubrutinib. ^May include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login